222 related articles for article (PubMed ID: 24297644)
1. Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
Huang YT; Cheng CC; Lin TC; Chiu TH; Lai PC
Oncol Rep; 2014 Feb; 31(2):771-80. PubMed ID: 24297644
[TBL] [Abstract][Full Text] [Related]
2. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
[TBL] [Abstract][Full Text] [Related]
3. Novel survivin inhibitor YM155 elicits cytotoxicity in glioblastoma cell lines with normal or deficiency DNA-dependent protein kinase activity.
Lai PC; Chen SH; Yang SH; Cheng CC; Chiu TH; Huang YT
Pediatr Neonatol; 2012 Jun; 53(3):199-204. PubMed ID: 22770110
[TBL] [Abstract][Full Text] [Related]
4. The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2.
Yoon DH; Shin JS; Jin DH; Hong SW; Jung KA; Kim SM; Hong YS; Kim KP; Lee JL; Suh C; Lee JS; Kim TW
Anticancer Res; 2012 May; 32(5):1681-8. PubMed ID: 22593446
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer.
Huang YT; Cheng CC; Chiu TH; Lai PC
Int J Oncol; 2015 Nov; 47(5):1711-24. PubMed ID: 26398114
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer.
Gazzaniga P; Silvestri I; Gradilone A; Scarpa S; Morrone S; Gandini O; Gianni W; Frati L; Aglianò AM
Anticancer Drugs; 2007 Feb; 18(2):179-85. PubMed ID: 17159604
[TBL] [Abstract][Full Text] [Related]
7. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
[TBL] [Abstract][Full Text] [Related]
8. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
[TBL] [Abstract][Full Text] [Related]
9. Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines.
Jane EP; Premkumar DR; Sutera PA; Cavaleri JM; Pollack IF
Mol Carcinog; 2017 Apr; 56(4):1251-1265. PubMed ID: 27805285
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
Zhao X; Puszyk WM; Lu Z; Ostrov DA; George TJ; Robertson KD; Liu C
Mol Cancer Ther; 2015 Jan; 14(1):80-9. PubMed ID: 25344582
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K⁺ channels.
Zhang S; Liu B; Fan Z; Wang D; Liu Y; Li J; Wang N; Liu Y; Zhang B
Mol Med Rep; 2016 Apr; 13(4):3415-22. PubMed ID: 26957114
[TBL] [Abstract][Full Text] [Related]
12. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
[TBL] [Abstract][Full Text] [Related]
13. Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells.
Wang Q; Chen Z; Diao X; Huang S
Cancer Lett; 2011 Mar; 302(1):29-36. PubMed ID: 21220185
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
15. Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells.
Chiou JT; Lee YC; Huang CH; Shi YJ; Wang LJ; Chang LS
Toxicol Appl Pharmacol; 2020 Jan; 387():114857. PubMed ID: 31837377
[TBL] [Abstract][Full Text] [Related]
16. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells.
Cheng SM; Chang YC; Liu CY; Lee JY; Chan HH; Kuo CW; Lin KY; Tsai SL; Chen SH; Li CF; Leung E; Kanwar JR; Huang CC; Chang JY; Cheung CH
Br J Pharmacol; 2015 Jan; 172(1):214-34. PubMed ID: 25220225
[TBL] [Abstract][Full Text] [Related]
17. Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma.
Wang YF; Zhang W; He KF; Liu B; Zhang L; Zhang WF; Kulkarni AB; Zhao YF; Sun ZJ
Apoptosis; 2014 Apr; 19(4):748-58. PubMed ID: 24370995
[TBL] [Abstract][Full Text] [Related]
18. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
Liang H; Zhang L; Xu R; Ju XL
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
[TBL] [Abstract][Full Text] [Related]
19. YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells.
Yan X; Su H
Med Sci Monit; 2017 Apr; 23():1963-1972. PubMed ID: 28435150
[TBL] [Abstract][Full Text] [Related]
20. Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.
Pinto-Leite R; Arantes-Rodrigues R; Palmeira C; Gaivão I; Cardoso ML; Colaço A; Santos L; Oliveira P
J Toxicol Environ Health A; 2012; 75(13-15):788-99. PubMed ID: 22788366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
